Overexpression of c-erbB-2 oncoprotein and associated pathobiological factors in invasive primary breast cancer

Indian Journal of Experimental Biology

Volumn 42, Issue 3, 2004, Pages 253-258

  Ray, Amitabha ^a   Sharma, Bhuvnesh Kumar ^a   Kaur, Sudershan ^a   Sharma, Shashi ^a   Sharma, Joginder Kumar ^a,b  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

Author keywords

Breast cancer; c erbB 2; EGF R menopausal status; Oncoprotein

Indexed keywords

IMMUNOLOGY; TISSUE; TUMORS;

BREAST CANCER; ESTROGEN RECEPTORS (ER);

PROTEINS;

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BIOSYNTHESIS; BREAST; BREAST TUMOR; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PHYSIOLOGY; POSTMENOPAUSE; PREMENOPAUSE;

ADULT; AGE FACTORS; AGED; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 1542290623     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Parkin D M, Bray F, Ferlay J & Pisani P, Estimating the world cancer burden: GLOBOCAN 2000, Int J Cancer, 94 (2001) 153.
2. Lanier A P, Kelly J J, Smith B, Harpster A P, Tanttila H, Amadon C, Beckworth D, Key C & Davidson A M, Alaska Native cancer update: Incidence rates 1989-1993, Cancer Epidemiol Biomarkers Prev, 5 (1996) 749.
3. Notani P N, Global variation in cancer incidence and mortality, Curr Sci, 81 (2001) 465.
4. National Cancer Registry Programme, Indian Council of Medical Research-New Delhi, 2001.
5. Dati C, Antoniotti S, Taverna D, Perroteau T & De Bortolia M, Inhibition of c-erbB-2 oncogene expression by estrogen in human breast cancer cells, Oncogene, 5 (1990) 1001.
6. Liu Y, el Ashry D, Chen D, Ding T Y & Kern F G, MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen depleted conditions and reduced estrogen dependence and tamoxifen sensitivity in vivo, Breast Cancer Res Treat, 34 (1995) 97.
7. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T & Toyoshima K, Similarity of protein encoded by human c-erbB-2 gene to EGF-receptor, Nature, 319 (1986) 230.
8. McCann A H, Dervan P A, O'Regan M, Codd M B, Gullick W J, Tobin B M J & Carney D N, Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer, Cancer Res, 51 (1991) 3296.
9. Jardines L, Weiss M, Fowble B & Greene M, Pathobiology, 61 (1993) 268.
10. Hung M C & Lau Y K, Basic science of HER-2/neu: A review, Semin Oncol, 26 Suppl. 12 (1999) 51.
11. Bloom H J C & Richardson W W, Histological grading and prognosis in breast cancer: A study of 1409 cases of which 356 have been followed for 15 years, Br J Cancer, 11 (1957) 359.
12. Dalton L W, Page D L & Dupont W D, Histologic gradation of breast cancer A reproducibility study, Cancer, 73 (1994) 2765.
13. Ray A, Naik S L D & Sharma B K, Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix, Indian J Physiol Pharmacol, 46 (2002) 423.
14. Rosen P P, Lesser M L, Arroyo C D, Cranor M, Borgen P & Norton L, Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: A study of epidemiologic features and prognosis, Cancer, 75 (1995) 1320.
15. 53 and c-erbB-2 proteins in breast cancer, J Pathol, 179 (1996) 31.
16. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, Terada M & Yamamoto H, Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: a retrospective analysis of 176 cases, Cancer, 65 (1990) 1794.
17. Bhatavdekar J M, Patel D D, Shah N G, Vora H H, Suthar T P, Chikhlikar P R, Ghosh N & Trivedi T I, Prognostic significance of immunohistochemically localized biomarkers in stage II and III breast cancer, A multivariate analysis, Ann Surg Oncol, 7 (2000) 305.
18. 53 and c-erbB-2 in breast cancer, Med B Aires, 55 (1995) 415.
19. 53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in-situ carcinomas of the breast, Eur J Cancer, 33 (1997) 39.
20. Bezwoda W R, c-erb-B-2 expression and response to treatment in metastatic breast cancer, Med Oncol, 17 (2000) 22.
21. Baselga J, Seidman A D, Rosen P P & Norton L, HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications, Oncology, 11 Suppl. 2 (1997) 43.
22. 53 and c-erbB-2 in lymph node negative breast cancer, Hum Pathol, 27 (1996) 955.
23. Gullick W J, The role of epidermal growth factor receptor and the c-erbB-2 protein in breast cancer, Int J Cancer, 5 Suppl. (1990) 55.
24. Nizze H, al-Thobhani A K & Terpe H, Steroid hormone receptors status and other immunohistochemical prognostic markers in benign and malignant diseases of the breast, Zentralbl Chir, 123 Suppl. 5 (1998) 14.
25. Clemmesen J, Measurement of levels of health, WHO Reg Publ, EURO Ser No. 7 (1979) 199.
26. Park K, Textbook of preventive and social medicine (Banarsidas Bhanot, Jabalpur) 2000, 58.
27. Pasqualini J R, Cherite G, Blacker C, Feinstein M C, Delanode L, Talbi M & Malocho C, Concentrations of estrone, estradiol and estrone sulfate and evaluation of sulfatase and aromatase activities in pre and postmenopausal breast cancer patients, J Clin Endocrinol Metab, 81 (1996) 1460.
28. Pasquali R, Vincennati V, Bertazzo D, Casimirri F, Pascal G, Tortelli O & Labate A M, Determinants of sex hormone binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status, Metabolism, 46 (1997) 5.
29. Masamura S, Santner S J, Gimoty P, George J & Santen R J, Mechanism for maintainance of high breast tumor estradiol concentrations in the absence of ovarian function: Role of very high affinity tissue uptake, Breast Cancer Res Treat, 42 (1997) 215.
30. Hislop T G, Coldman A J, Elwood J M, Skippen D H & Kan L, Relationship between risk factors for breast cancer and hormonal status, Int J Epidemiol, 15 (1986) 469.